[go: up one dir, main page]

PL3203997T3 - Kwas walproinowy do leczenia lub zapobiegania stanom patologicznym związanym z nadmiernym odkładaniem się fibryny i/lub tworzeniem zakrzepów - Google Patents

Kwas walproinowy do leczenia lub zapobiegania stanom patologicznym związanym z nadmiernym odkładaniem się fibryny i/lub tworzeniem zakrzepów

Info

Publication number
PL3203997T3
PL3203997T3 PL15790632T PL15790632T PL3203997T3 PL 3203997 T3 PL3203997 T3 PL 3203997T3 PL 15790632 T PL15790632 T PL 15790632T PL 15790632 T PL15790632 T PL 15790632T PL 3203997 T3 PL3203997 T3 PL 3203997T3
Authority
PL
Poland
Prior art keywords
clothes
prevention
treatment
pathological conditions
valproic acid
Prior art date
Application number
PL15790632T
Other languages
English (en)
Inventor
Sverker JERN
Jonas Faijerson SÄLJÖ
Niklas BERGH
Original Assignee
Cereno Scientific Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cereno Scientific Ab filed Critical Cereno Scientific Ab
Publication of PL3203997T3 publication Critical patent/PL3203997T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL15790632T 2014-10-08 2015-10-08 Kwas walproinowy do leczenia lub zapobiegania stanom patologicznym związanym z nadmiernym odkładaniem się fibryny i/lub tworzeniem zakrzepów PL3203997T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1417828.9A GB201417828D0 (en) 2014-10-08 2014-10-08 New methods and compositions
PCT/GB2015/052950 WO2016055797A2 (en) 2014-10-08 2015-10-08 Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
EP15790632.2A EP3203997B1 (en) 2014-10-08 2015-10-08 Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation

Publications (1)

Publication Number Publication Date
PL3203997T3 true PL3203997T3 (pl) 2022-05-16

Family

ID=51947070

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15790632T PL3203997T3 (pl) 2014-10-08 2015-10-08 Kwas walproinowy do leczenia lub zapobiegania stanom patologicznym związanym z nadmiernym odkładaniem się fibryny i/lub tworzeniem zakrzepów

Country Status (20)

Country Link
US (4) US10111845B2 (pl)
EP (2) EP3203997B1 (pl)
JP (2) JP6787901B2 (pl)
KR (2) KR20170063857A (pl)
CN (3) CN115581691A (pl)
AU (1) AU2015329795B2 (pl)
BR (1) BR112017007144A2 (pl)
CA (2) CA2964041C (pl)
CL (1) CL2017000866A1 (pl)
DK (1) DK3203997T3 (pl)
ES (1) ES2913225T3 (pl)
GB (1) GB201417828D0 (pl)
HU (1) HUE058316T2 (pl)
IL (1) IL251142B (pl)
MX (2) MX2017004558A (pl)
MY (1) MY192055A (pl)
PL (1) PL3203997T3 (pl)
RU (1) RU2732761C2 (pl)
SG (1) SG11201702058XA (pl)
WO (1) WO2016055797A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59534B1 (sr) 2014-02-13 2019-12-31 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
PH12020552066A1 (en) 2014-02-13 2022-05-11 Incyte Corp Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
EP3626720A1 (en) 2015-04-03 2020-03-25 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
MX389824B (es) 2015-08-12 2025-03-20 Incyte Holdings Corp Sales de un inhibidor de dimetilasa 1 especifica para lisina (lsd1).
WO2017175010A1 (en) * 2016-04-08 2017-10-12 Cereno Scientific Ab Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
CN114209667A (zh) 2016-04-08 2022-03-22 赛伦诺科技有限公司 包含丙戊酸的延迟释放药物制剂和其用途
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2021146257A1 (en) * 2020-01-16 2021-07-22 The Regents Of The University Of Michigan Concentrated sodium valproate for rapid delivery
CN111450072B (zh) * 2020-05-07 2022-07-15 江苏艾立康医药科技有限公司 一种替格瑞洛控释片及其制备方法
GB2613900B (en) * 2021-12-20 2024-01-17 Cereno Scient Ab Novel compounds and methods of use thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DE3773926D1 (de) 1987-07-22 1991-11-21 Farvalsa Ag Feuchtigkeitsstabile feste valproinsaeure-zubereitung und verfahren zu ihrer herstellung.
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE9402422D0 (sv) 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
US6713086B2 (en) * 1998-12-18 2004-03-30 Abbott Laboratories Controlled release formulation of divalproex sodium
HK1042427A1 (zh) 1999-09-30 2002-08-16 Penwest Pharmaceuticals Co. 用於高溶度药物的持续释放基质方法
AT408718B (de) 1999-12-02 2002-02-25 Gerot Pharmazeutika Natriumvalproat-granulat mit verringerter hygroskopizität
AU2002243231A1 (en) 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
ITMI20011733A1 (it) 2001-08-07 2003-02-07 Italfarmaco Spa Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
US7090858B2 (en) 2001-08-09 2006-08-15 Swaminathan Jayaraman Coated filter bag material for oral administration of medicament in liquid and methods of making same
EP1509236A4 (en) 2002-05-13 2008-07-30 Children S Hospital Los Angele TREATMENT AND PREVENTION OF ABNORMAL SCALING IN KELOIDS AND OTHER SKIN OR INTERNAL WOUNDS OR LESIONS
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US20040224006A1 (en) 2003-04-21 2004-11-11 Samn Raffaniello Ancrod irradiated, impregnated or coated sutures and other first aid or wound management bandaging materials for minimizing scarring and/or preventing excessive scar formation
ITMI20040876A1 (it) 2004-04-30 2004-07-30 Univ Degli Studi Milano Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari
SI1591109T1 (sl) 2004-04-30 2008-10-31 Topotarget Germany Ag Formulacija, ki obsega inhibitor histon-deacetilaze in izkazuje dvofazno sproščanje
US20050276848A1 (en) 2004-06-15 2005-12-15 Nilobon Podhipleux Sustained release neutralized divalproex sodium
US7713550B2 (en) * 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
WO2006117165A2 (en) 2005-05-02 2006-11-09 Friedrich-Alexander-Universität Erlangen-Nürnberg Means and methods for the treatment of head injuries and stroke
EP1743654A1 (en) 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
AU2006287378A1 (en) 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by HDac inhibition
PL1937650T3 (pl) 2005-09-08 2011-11-30 Mei Pharma Inc Związki heterocykliczne
ES2317450T3 (es) 2006-01-11 2009-04-16 Teva Pharmaceutical Industries Ltd. Formulacion de liberacion controlada de acido valproico y sus derivados.
WO2007084775A2 (en) 2006-01-20 2007-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
US20090312311A1 (en) 2006-04-06 2009-12-17 Gary Michael Ksander Combination of organic compounds
CA2661683C (en) 2006-08-31 2015-11-24 Eurand, Inc Drug delivery systems comprising solid solutions of weakly basic drugs
EP2167090A4 (en) 2007-06-06 2010-08-25 Univ Maryland HDAC INHIBITORS AND HORMONE TREATMENT MEDICAMENTS
US20090270497A1 (en) 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
GB201003766D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
CN101947209B (zh) 2010-07-21 2012-07-25 河南中帅医药科技发展有限公司 双丙戊酸钠小丸及其制备方法
WO2012120262A1 (en) * 2011-03-09 2012-09-13 Larsson Pia Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors
NZ621221A (en) 2011-09-13 2016-07-29 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
CN114209667A (zh) 2016-04-08 2022-03-22 赛伦诺科技有限公司 包含丙戊酸的延迟释放药物制剂和其用途
WO2017175010A1 (en) 2016-04-08 2017-10-12 Cereno Scientific Ab Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation

Also Published As

Publication number Publication date
EP4066825A1 (en) 2022-10-05
JP2017532376A (ja) 2017-11-02
RU2017114933A (ru) 2018-11-12
EP3203997A2 (en) 2017-08-16
EP3203997B1 (en) 2022-03-02
US12245999B2 (en) 2025-03-11
JP7305605B2 (ja) 2023-07-10
IL251142A0 (en) 2017-04-30
WO2016055797A2 (en) 2016-04-14
BR112017007144A2 (pt) 2017-12-19
RU2017114933A3 (pl) 2019-05-16
CN107205975A (zh) 2017-09-26
MX2022007221A (es) 2022-07-12
GB201417828D0 (en) 2014-11-19
US20180177751A1 (en) 2018-06-28
HUE058316T2 (hu) 2022-07-28
KR20250005512A (ko) 2025-01-09
DK3203997T3 (da) 2022-05-23
WO2016055797A3 (en) 2016-06-09
RU2732761C2 (ru) 2020-09-22
MY192055A (en) 2022-07-25
IL251142B (en) 2022-07-01
KR20170063857A (ko) 2017-06-08
US10111845B2 (en) 2018-10-30
CA3234641A1 (en) 2016-04-14
ES2913225T3 (es) 2022-06-01
CA2964041C (en) 2024-04-09
CL2017000866A1 (es) 2017-11-24
CA2964041A1 (en) 2016-04-14
AU2015329795A1 (en) 2017-04-13
MX2017004558A (es) 2017-12-14
NZ730307A (en) 2024-01-26
CN115721635A (zh) 2023-03-03
US11400064B2 (en) 2022-08-02
US20250241880A1 (en) 2025-07-31
US20190015360A1 (en) 2019-01-17
SG11201702058XA (en) 2017-04-27
AU2015329795B2 (en) 2021-03-25
JP6787901B2 (ja) 2020-11-18
US20220401393A1 (en) 2022-12-22
CN115581691A (zh) 2023-01-10
JP2021008523A (ja) 2021-01-28

Similar Documents

Publication Publication Date Title
PL3203997T3 (pl) Kwas walproinowy do leczenia lub zapobiegania stanom patologicznym związanym z nadmiernym odkładaniem się fibryny i/lub tworzeniem zakrzepów
EP3695666A4 (en) DETECTION OF DRIVING ACTIONS THAT REDUCE THE RISK
EP3261641A4 (en) PANKREATITISBEHANDLUNG
EP3370721A4 (en) TREATMENT OF OSTEOARTHRITIS
FR3046933B1 (fr) Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
EP4015648C0 (en) REDUCTION OF INTRON RETENTION
EP3263132C0 (en) Composition for treating il-6-related diseases
IL243485A0 (en) Methods for treating or preventing ophthalmological conditions
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
EP2968208A4 (en) TREATMENT OF CATAPLEXIA
EP3875139C0 (en) TREATMENT OF VENOUS DISEASES
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
EP3193862C0 (en) TOPICAL COMPOSITION OF CANNABINOIDS FOR THE TREATMENT OF ARTHRITIS PAIN
EP2945639A4 (en) METHOD FOR THE TREATMENT OF HEART DISEASES
EP4088724C0 (en) ACETYLCHOLINESTERASE INHIBITORS FOR THE ORAL TREATMENT OF DERMATOLOGICAL CONDITIONS
IL246269B (en) Compositions and methods for treating fatty tissue buildup
PL3393468T3 (pl) Metody leczenia niedoboru odporności
IL257764B (en) Methods for treatment of diseases
EP3283115C0 (en) COMPOSITIONS FOR THE TREATMENT OF AUTISM
EP3365477A4 (en) CORROSION RESISTANCE
IL248567A0 (en) Using compounds known as d-amino acid oxidase inhibitors
EP2968084A4 (en) COMPOSITIONS FOR THE TREATMENT OF XEROSTOMY AND DENTAL TREATMENT
EP3348278A4 (en) Exosome secretion inhibitors
MA40687A (fr) Méthodes et compositions de traitement de malformation vasculaire
PL3373922T3 (pl) Kompozycje i sposoby do stosowania do leczenia homocystynurii